Search research articles
Contact Us
Filters
Showing results (151-160 of 154) with videos related to
Page
of 16
Sort By:
You have reached the last page of results.
This site can display upto 154 results.
EJNMMI Research
|
March 1, 2026
A phase II study evaluating pharmacokinetics and dosimetry of <sup>177</sup>Lu-PSMA-617 radioligand therapy in Chinese participants with progressive metastatic castration-resistant prostate cancer
Hongcheng Shi, Jianming Guo, Wei Fan, et al.
Nature Genetics
|
April 1, 2025
Spatially resolved transcriptomic analysis of the adult human prostate
Junyi Hu, Fei Liu, Jing Zhang, et al.
World Journal of Pediatrics : WJP
|
March 3, 2026
Gene-based burden testing implicates four novel susceptibility genes associated with isolated short stature in pediatric patients
Fei Xiao, Ming-Yue Cai, Bing-Yu Yang, et al.
Journal for Immunotherapy of Cancer
|
March 22, 2023
Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)
Bilal A Siddiqui, Brian F Chapin, Sonali Jindal, et al.
Page
of 16
Search research articles
Search
Showing results (151-160 of 154) with videos related to
Sort By:
Page
of 16
You have reached the last page of results.
This site can display upto 154 results.
EJNMMI Research
|
March 1, 2026
A phase II study evaluating pharmacokinetics and dosimetry of <sup>177</sup>Lu-PSMA-617 radioligand therapy in Chinese participants with progressive metastatic castration-resistant prostate cancer
Hongcheng Shi, Jianming Guo, Wei Fan, et al.
Nature Genetics
|
April 1, 2025
Spatially resolved transcriptomic analysis of the adult human prostate
Junyi Hu, Fei Liu, Jing Zhang, et al.
World Journal of Pediatrics : WJP
|
March 3, 2026
Gene-based burden testing implicates four novel susceptibility genes associated with isolated short stature in pediatric patients
Fei Xiao, Ming-Yue Cai, Bing-Yu Yang, et al.
Journal for Immunotherapy of Cancer
|
March 22, 2023
Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)
Bilal A Siddiqui, Brian F Chapin, Sonali Jindal, et al.
Page
of 16